These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18573526)

  • 1. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
    Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.
    Tiesmeier J; Müller-Tidow C; Westermann A; Czwalinna A; Hoffmann M; Krauter J; Heil G; Ganser A; Serve H; Verbeek W
    Leuk Res; 2004 Oct; 28(10):1069-74. PubMed ID: 15289019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    Lee SH; Paietta E; Racevskis J; Wiernik PH
    Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
    [No Abstract]   [Full Text] [Related]  

  • 7. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).
    Doubek M; Muzík J; Szotkowski T; Koza V; Cetkovský P; Kozák T; Zák P; Voglová J; Struncová S; Dusek L; Indrák K
    Neoplasma; 2007; 54(1):89-94. PubMed ID: 17233551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
    Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
    [No Abstract]   [Full Text] [Related]  

  • 10. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
    Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
    Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
    Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
    Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
    J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence and clinical significance of FLT3 internal tandem duplication mutation in acute leukemia].
    Wang LH; Zhou CL; Zhang XW; Chen S; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):393-6. PubMed ID: 15355689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
    Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
    Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
    Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS
    Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
    Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
    Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
    Xu B; Shi PC; Song XY; Tang JH; Zhou SY
    Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
    Sorà F; Chiusolo P; Metafuni E; Bellesi S; Giammarco S; Laurenti L; Ausoni G; Zini G; Bayer AJ; Mario B; Leone G; Sica S
    Leuk Res; 2011 Mar; 35(3):422-3. PubMed ID: 21093053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.